Dosing regimens for venous thromboembolism prophylaxis.*
| Regimen . | Dose . |
|---|---|
| *These dosing regimens are not FDA approved for this indication. | |
| Abbreviations: UFH, unfractionated heparin; LWMH, low-molecular-weight heparin | |
| Prophylactic UFH | UFH 5000 U subcutaneously every 12 hours |
| Intermediate-dose UFH | UFH subcutaneously every 12 hours in doses adjusted to target an anti-Xa level of 0.1–0.3 U/mL |
| Prophylactic LMWH | Enoxaparin 40 mg subcutaneously every 24 hours Dalteparin 5000 units subcutaneously every 24 hours Tinzaparin 4500 units or 75 units/kg subcutaneously every 24 hours |
| Intermediate-dose prophylactic LMWH | Dalteparin 5000 U subcutaneously every 12 hours Enoxaparin 40 mg subcutaneously every 12 hours LMWH subcutaneously every 24 hours adjusted to achieve a peak anti-Xa level of 0.2–0.6 U/mL |
| Regimen . | Dose . |
|---|---|
| *These dosing regimens are not FDA approved for this indication. | |
| Abbreviations: UFH, unfractionated heparin; LWMH, low-molecular-weight heparin | |
| Prophylactic UFH | UFH 5000 U subcutaneously every 12 hours |
| Intermediate-dose UFH | UFH subcutaneously every 12 hours in doses adjusted to target an anti-Xa level of 0.1–0.3 U/mL |
| Prophylactic LMWH | Enoxaparin 40 mg subcutaneously every 24 hours Dalteparin 5000 units subcutaneously every 24 hours Tinzaparin 4500 units or 75 units/kg subcutaneously every 24 hours |
| Intermediate-dose prophylactic LMWH | Dalteparin 5000 U subcutaneously every 12 hours Enoxaparin 40 mg subcutaneously every 12 hours LMWH subcutaneously every 24 hours adjusted to achieve a peak anti-Xa level of 0.2–0.6 U/mL |